|
DGAP-Ad-hoc: Dermapharm Holding SE / Key word(s): Takeover Disclosure of insider information pursuant to Section 17 (1) 1 of Regulation (EU)
Grünwald, December 15, 2021 - Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8), through Dermapharm AG, today entered into an agreement with Canopy Growth Germany GmbH, based in St. Leon-Rot, Germany, to acquire C³ Cannabinoid Compound GmbH, based in Neumarkt, Germany, and its subsidiaries Spectrum Therapeutics GmbH, based in Neumarkt, Germany, THC Pharm GmbH The Health Concept, based in Frankfurt, Germany, and Spectrum Therapeutics Austria GmbH, based in Vienna, Austria. Upon completion of the transaction, Dermapharm AG will acquire 100.00 percent of the shares in the company, which specializes in the development, production and marketing of natural and synthetic active pharmaceutical ingredients based on cannabinoids. The purchase price is in the order of EUR 80 million plus possible performance-based limited purchase price components. The closing of the transaction is subject to the approval of the antitrust authorities. The Management Board expects the transaction to be completed by the end of January 2022.
Contact Investor Relations & Corporate Communications
15-Dec-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Dermapharm Holding SE |
| Lil-Dagover-Ring 7 | |
| 82031 Grünwald | |
| Germany | |
| Phone: | +49 (0)89 64 86-0 |
| E-mail: | ir@dermapharm.com |
| Internet: | ir.dermapharm.de |
| ISIN: | DE000A2GS5D8 |
| WKN: | A2GS5D |
| Indices: | SDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1258267 |
| End of Announcement | DGAP News Service |
|
|
1258267 15-Dec-2021 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
